---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033071"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T10:54:19.102109+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive

## Summary
- Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.
- Revenue $0.7M Q4 vs $7.2M YoY; full-year $2.8M vs $21.0M, due to Amgen collaboration timing.
- Cash, equivalents and marketable securities $290.1M; funding into Q1 2027.
- ASH heme trial: 2/26 (8%) relapsed vs 4/12 (33%) control; HR 0.30.
- IND cleared for MAGE-A4 TCR-T; closed $30M registered direct offering at 37% premium.

## SEC filing metadata
- accession: 0000950170-25-033071
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/0000950170-25-033071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/tcrx-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033071
- JSON: https://secwatch.observer/filing/0000950170-25-033071.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.